ASCO 2023 | Prognostic value of early bone marrow and PET MRD assessment in CAR-T therapy for multiple myeloma
Yi Lin, MD, PhD, Mayo Clinic, Rochester, MN, discusses the prognostic value of early bone marrow measurable residual disease (MRD) assessment following CAR-T therapy in multiple myeloma. A recent study found that patients who achieve MRD negativity and free light chain clearance one month after CAR-T have better outcomes. Conversely, MRD positivity and residual free light chain levels after one month indicate a higher risk of relapse and a lower rate of durable response. A follow-up study demonstrated that negative results in both early bone marrow and PET MRD assessments serve as the strongest prognostic indicator for CAR-T therapy outcomes. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
